initial public offerings (IPOs) trading on American exchanges
Showing posts with label 6-year performance. Show all posts
Showing posts with label 6-year performance. Show all posts

Thursday, June 18, 2026

Legend Biotech (LEGN) prices offering of 7.7 mln ADSs at $29.35 per ADS

  • Legend Biotech prices 7.7 million ADS underwritten offering at $29.35 each for expected gross proceeds of approximately $226 million
  •  Legend Biotech (NASDAQ: LEGN) went public on June 5, 2020, raising approximately $424 million in its initial public offering (IPO). The company originally offered 18.4 million American Depositary Shares (ADS) at a price of $23.00 per share.
  • https://legendbiotech.com/







Tuesday, August 5, 2025

TransMedics Group (TMDX) : 6-year performance

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. 
  • Sector: Healthcare
  • Industry: Medical Devices
  • Full Time Employees: 728
  • Founded in 1998 
  • Headquartered in Andover, Massachusetts.
  • https://www.transmedics.com
 
 


TransMedics is in the business of providing the technology for organ transplants. Its Organ Care System (OCS) allows donor organs to be preserved in a living and functioning state by supplying oxygenated blood while they are being transported.

The OCS system sidesteps the limitations of using ice to transport organs such as the heart, liver or lungs. Organs placed in ice for extended periods of time are at risk of being damaged. According to the company, the OCS method has an added advantage since the system allows doctors to assess the organ's viability – something that is difficult to do when the organ is metabolically inactive in cold storage.

On Monday, shares rose 7%, extending a winning streak to four days after the FDA gave an investigational device exemption for OCS in a new clinical trial for heart transplants. The two-phase trial will test longer perfusion time (passage of blood) for heart transplants using OCS and assess the system's ability to support heart transplants from donors after brain death. The trial is expected to exceed 650 patients and may be the largest clinical trial conducted for heart preservation for transplant purposes.

Monday, January 27, 2025

Allakos (ALLK) : topline results from its phase 1 trial of AK006 in patients with chronic spontaneous urticaria

– AK006 did not demonstrate therapeutic activity in CSU
– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives
 
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.
  • Sector: Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 131
  • Incorporated in 2012 
  • Headquartered in San Carlos, California
  • https://www.allakos.com
IPO: July 19, 2018; Allakos priced an upsized 7.2 million shares offering at 18, above the expected range of 15 to 17. Shares closed at 31.25, up 73.6% on the first trading day.





Allakos announces topline results from its phase 1 trial of AK006 in patients with chronic spontaneous urticaria and announces restructuring 
  • Co announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).
  • "While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has decided to discontinue further clinical development of AK006," said Chin Lee, M.D, M.P.H., Chief Medical Officer of Allakos. "We express our gratitude to all of the patients, clinical trial investigators, and site coordinators in these trials."
  • The Company ended the fourth quarter of 2024 with approximately $81 million in cash, cash equivalents, and investments (unaudited).
  • The Company estimates that cash used in restructuring activities to closeout AK006 development, including severance and contractual payments to vendors, will be approximately $34 million to $38 million. The
  • Company also estimates that a significant majority of these restructuring costs will be paid over the first and second quarters of 2025.
  • The Company estimates it will have cash, cash equivalents and investments in a range of approximately $35 million to $40 million at June 30, 2025.


Friday, November 1, 2024

Iterum Therapeutics (ITRM) : 6-year performance

  • Sector(s): HealthcareIndustry: Biotechnology
  • Full Time Employees: 14
  • Incorporated in 2015 
  • Headquartered in Dublin, Ireland
  • https://www.iterumtx.com
 


 
 


Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has submitted an NDA for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://www.iterumtx.com.

Wednesday, October 23, 2024

Aquestive Therapeutics (AQST) : 6-year performance

  •  Sector(s): Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Full Time Employees: 135
  • Headquarters: Warren, New Jersey 
  • Founded: 2004
  • https://www.aquestive.com
IPO July 25, 2018: 4,500,000 shares of common stock at a public offering price of $15.00 per share.




Friday, May 17, 2024

Gritstone Oncology (GRTS) : 6-year performance

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. 
  • Headquarters: Emeryville, California
  • Founded: August 2015
  • IPO: September 28, 2018
  • The company changed its name to Gritstone bio, Inc. in May 2021. 
  • Ticker: GRTS
Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. 





The company reported on clinical trial outcomes for its cancer vaccine, GRANITE. Although some data were promising, particularly in certain patient subgroups, the overall results were not as compelling as hoped, leading to stock price declines.

On October 10, 2024, Gritstone bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

The company's shares were delisted from Nasdaq following its bankruptcy filing, with trading suspension announced to start on October 22, 2024. The stock symbol transitioned to GRTSQ due to the bankruptcy proceedings.
 
Oct 18, 24:
 
 

Tuesday, July 27, 2021

Inovalon (INOV) to be acquired by Nordic Capital?

  • Update: Acquired by Nordic Capital and Insight Partners for $7.3 Billion. (Aug 19, 2021) 
(Bloomberg) -- Private equity firm Nordic Capital is in advanced talks on a potential acquisition of health-care technology company Inovalon Holdings Inc., according to people familiar with the matter.

A final agreement hasn’t been reached and discussions could still fall apart, said the people, who asked not to be identified because the information was private. Representatives for Nordic Capital and Inovalon didn’t immediately respond to requests for comment outside of normal business hours.

 
 
 
 
 


 
Shares of Inovalon have risen about 80% this year through Monday, giving it a market value of about $5.1 billion. Inovalon jumped as much as 13% in pre-market U.S. trading Tuesday.

Inovalon, based in Bowie, Maryland, went public in 2015 in an initial public offering that raised about $685 million. The company’s software is used to aggregate and analyze health-care data from researchers and providers, according to its website.

Its database includes information from more than 1 million physicians, 580,000 clinical facilities and 336 million patients. The software is used by all of the top 25 U.S. health plans as well as the world’s top 25 pharmaceutical companies, the company said. Inovalon is scheduled to report its second-quarter earnings on July 28.

Based in Stockholm, Nordic Capital has raised more than 1.2 billion euros ($1.4 billion) for a new fund intended to invest 35 million euros to 150 million euros in health care, technology and financial services firms across northern Europe.

On Monday, it agreed to invest in Dutch outpatient health-care provider Equipe Zorgbedrijven. That followed a roughly $846 million deal in June for speciality pharmaceutical company Advanz Pharma, and the agreement in March to acquire a stake in Danish dermatology firm LEO Pharma A/S.

Private equity firms have agreed $106 billion of acquisitions in the health-care sector globally this year, according to data compiled by Bloomberg. That’s up more than 300% on the same period in 2020, the data show.

Thursday, May 27, 2021

Ollie's Bargain Outlet (OLLI) reported earnings on Thur 27 May 21 (a/h)

  ** charts after earnings **



Ollie's Bargain Outlet beats by $0.18, beats on revs 
  • Reports Q1 (Apr) earnings of $0.80 per share, excluding non-recurring items, $0.18 better than the S&P Capital IQ Consensus of $0.62; revenues rose 29.5% year/year to $452.5 mln vs the $422.13 mln S&P Capital IQ Consensus.
    • Comparable store sales increased 18.8%.
    • Gross margin increased 20 basis points to 40.4% in the first quarter of fiscal 2021 from 40.2% in the first quarter of fiscal 2020. The increase in gross margin in the first quarter of fiscal 2021 is due to improvement in merchandise margin, partially offset by increases in and deleveraging of supply chain costs, primarily the result of higher transportation expenses.
  • The Company continues to monitor the impact of the COVID-19 pandemic on the broader economy and, more specifically, its associates, customers, business partners and supply chain. Given the vast uncertainties regarding the pace of economic recovery and consumer demand amidst the ongoing pandemic, the Company is continuing its practice of not providing guidance for fiscal 2021.
  • Saturday, May 30, 2020

    Goldman Sachs MLP (GMZ); MLP and Energy Renaissance Fund (GER) : 6- and 7-year performance






    April 13, 2020
    Goldman Sachs Asset Management ("GSAM"), investment adviser for the Goldman Sachs MLP Income Opportunities Fund (GMZ) and Goldman Sachs MLP and Energy Renaissance Fund (GER) (together, the "Funds"), announced today that GMZ effected a 7-for-1 reverse share split and GER effected a 9-for-1 reverse share split for each Fund’s issued and outstanding common shares effective after the market close on April 13, 2020. The Funds’ common shares will begin trading on a split-adjusted basis when the market opens on April 14, 2020.

    The Funds

    Each Fund is a non-diversified, closed-end management investment company managed by GSAM’s Energy & Infrastructure Team, which is among the industry’s largest master limited partnerships ("MLP") investment groups. The Goldman Sachs MLP Income Opportunities Fund began trading on the NYSE on November 26, 2013, and the Goldman Sachs MLP and Energy Renaissance Fund began trading on the NYSE on September 26, 2014.

    Each Fund seeks a high level of total return with an emphasis on current distributions to shareholders. The Goldman Sachs MLP Income Opportunities Fund invests primarily in MLP investments. The Goldman Sachs MLP and Energy Renaissance Fund invests primarily in MLPs and other energy investments. Each Fund currently expects to concentrate its investments in the energy sector, with an emphasis on midstream MLP investments. The Goldman Sachs MLP and Energy Renaissance Fund invests across the energy value chain, including upstream, midstream and downstream investments.

    Friday, April 17, 2020

    Eros International (EROS) to merge with STX Entertainment

    •  Indian movie producer Eros International Plc is merging with privately-held U.S. filmmaker STX Entertainment in an all-stock deal that brings together Bollywood and Hollywood. 







    Bollywood Meets Hollywood With Marriage of Eros and STX
    (Bloomberg) -- Indian movie producer Eros International Plc is merging with privately-held U.S. filmmaker STX Entertainment in an all-stock deal that brings together Bollywood and Hollywood.

    The combined company, to be known as Eros STX Global Corp., will be publicly traded and have a valuation of more than $1 billion, including debt, according to people familiar with the details, who asked not to be identified as the matter is private. Eros’s New York-listed stock jumped as much as 77%, and closed a $3.05 in New York.

    It’s a rare deal in a mergers and acquisitions market that’s all but seized up as executives and investors grapple with the fallout from the pandemic.

    Although discussions began six months ago, final terms were hammered out in recent weeks over conference calls, with part of the Eros deal team dialing in from India. The transaction was signed virtually by an exchange of signature pages between lawyers, the people said. Eros founder Kishore Lulla said his long-standing relationship and trust in his STX counterpart Robert Simonds, for whom his daughter was once an intern, was key to getting a deal completed under unusual circumstances.

    Ultimately, the pandemic underscored the importance of the deal.

    “I was always a believer that technology is going to change the studio model and everything is going to shift to digital,” said Lulla, who will be co-chairman alongside Simonds. “Covid escalated that digital model.”

    In the last four to six weeks, the amount of time users spend on the platform jumped between 50% and 200%, Lulla said.

    Bigger Footprint

    But both companies have had their struggles over the years, and it’s too early to tell how much the combination will resolve them. STX has failed to find much of a winning formula at the box office, with modest recent performers like “Brahms: The Boy 2” and “The Gentlemen.” Eros, meanwhile, has become the target of short sellers who published reports on accounting irregularities. When the company posted a surge in revenue from the UAE in 2015, it was vague about the reasons, rankling investors.

    Joining forces will give the two independent companies more heft to compete with bigger studios as trends sweeping Hollywood have made it hard for smaller players to gain scale. Between Comcast Corp.’s Universal Pictures, the combination of Walt Disney Co. and Fox Corp.’s film companies, and AT&T Inc.’s acquisition of Time Warner Inc., a trio of studios now own and produce many of the most well-known blockbuster movie franchises, including the Marvel superhero universe and DC Comics. The result is a small group of big films increasingly dominating the box office.

    The deal will give the company a bigger geographical footprint.

    “My personal dream was always to be an important premium content provider globally in the markets that actually matter -- US, India and China -- and this combination is all three of those,” said Simonds, who will become chief executive officer of the company.

    STX films include comedian Amy Schumer’s “I Feel Pretty” and Jennifer Lopez’s “Hustlers”. The combined company expects to release 40 feature-length films this year, as well as content for services such as Netflix, Hulu and Amazon.

    The combined company will have $600 million in pro forma revenue for 2019 and $300 million of “highly predictable” future revenue from STX films that have already been released. There will be about $50 million in operating synergies.

    The company will be domiciled in the Isle of Man with joint headquarters in Maharashtra, India and Burbank, California.

    The deal comes less than two years after STX, which is backed by internet giant Tencent Holdings Ltd., shelved its IPO plans.

    STX’s backers TPG, Hony Capital and Liberty Global will provide some equity for the deal. The company will also have a $350 million credit facility led by JPMorgan Chase & Co.

    Citigroup advised Eros on the deal, while Gibson, Dunn & Crutcher provided legal advice. STX was advised by PJT Partners, with Kirkland & Ellis its legal adviser.

    Friday, November 22, 2019

    Extended Stay America (STAY) names Bruce Haase CEO, effective immediately

    Note: acquired by Blackstone Real Estate and the Starwood Capital Group (June 2021)

    Extended Stay America, Inc., the largest owner/operator of company-branded hotels in North America, owns and operates 682 hotels in the U.S. and Canada comprising approximately 76,000 rooms and employs approximately 10,000 employees in its hotel properties and headquarters.







    Extended Stay America names Bruce Haase CEO, effective immediately

  • Haase succeeds Jonathan Halkyard, who will continue to advise the company through February 25, 2020.
  • Haase has served as a director of ESH Hospitality since 2018. He has more than 20 years of lodging experience with particular expertise in the extended stay hotel segment.
  • The company also announced today the appointment of Kelly Poling as Executive Vice President, Chief Commercial Officer, and Randy Fox, as Executive Vice President, Property Operations.
  • Sunday, October 20, 2019

    USA Compression Partners (USAC) : 6-year performance

    USA Compression's business involves compressing natural gas to move it in pipelines, and since NG production continues to increase, so is demand for USAC's services.
    USAC has never cut its super-high distribution, even in a challenging macro environment (in 2015/16), and continually improving metrics give great comfort that the 12% distribution is safe.

     






    The Energy Information Administration (EIA) - the source of the above graph and of extensive data on energy in the US and abroad - states that domestic NG production averaged 83 BCF (billion cubic feet) per day in 2018, and EIA projects that NG production will average 90 BCF/day in 2019 and 92 BCF/day in 2020 (an 11% increase in US NG production between 2018 and 2020).


    Note that the 2 BCF/day growth in NG production expected between 2019 and 2020 is a marked deceleration from the torrid (and unsustainable) growth rate of the past two years.